Scholarlink

<p>Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of <i>MUC16</i> (CA125), <i>MUC4</i>, and <i>KRT24</i>. This cell state is enriched in metastases, predicted to be highly resistant to&#xa0;chemotherapy, and linked with poor survival. We also find enriched expression of <i>TM4SF1</i>, a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro&#xa0;and in vivo activity against bladder cancer cell lines in a <i>TM4SF1</i> expression-dependent manner, highlighting its potential as a therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月17日

查看全文
  • Heiko Yang,
  • Hanbing Song,
  • Elizabeth Yip,
  • Timothy Gilpatrick,
  • Kevin Chang,
  • Paul Allegakoen,
  • Kevin L. Lu,
  • Keliana Hui,
  • Julia H. Pham,
  • Corynn Kasap,
  • Vipul Kumar,
  • Janae Gayle,
  • Bradley A. Stohr,
  • Chien-Kuang Cornelia Ding,
  • Arun P. Wiita,
  • Maxwell V. Meng,
  • Jonathan Chou,
  • Sima P. Porten,
  • Franklin W. Huang

摘要

Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of MUC16 (CA125), MUC4, and KRT24. This cell state is enriched in metastases, predicted to be highly resistant to chemotherapy, and linked with poor survival. We also find enriched expression of TM4SF1, a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro and in vivo activity against bladder cancer cell lines in a TM4SF1 expression-dependent manner, highlighting its potential as a therapeutic target.